InVivo Therapeutics CSO Ulich Loses Job in Corporate Restructuring

Xconomy Boston — 

Thomas Ulich, chief scientific officer of InVivo Therapeutics (NASDAQ: NVIV) since 2015, is out of a job. The Cambridge, MA, biotech is eliminating 13 positions, including Ulich’s, as part of a corporate restructuring, according to regulatory filings. InVivo says the restructuring will help the company focus its resources on its experimental treatment for spinal cord injury.